BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ. Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases. World J Methodol 2014; 4(4): 197-218 [PMID: 25541601 DOI: 10.5662/wjm.v4.i4.197] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Kontoghiorghes GJ. The aim of iron chelation therapy in thalassaemia. Eur J Haematol 2017;99:465-6. [PMID: 28833560 DOI: 10.1111/ejh.12939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
2 Delatycki MB, Alkuraya F, Archibald A, Castellani C, Cornel M, Grody WW, Henneman L, Ioannides AS, Kirk E, Laing N, Lucassen A, Massie J, Schuurmans J, Thong M, Langen I, Zlotogora J. International perspectives on the implementation of reproductive carrier screening. Prenatal Diagnosis 2019;40:301-10. [DOI: 10.1002/pd.5611] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
3 Abu-Shaheen A, Heena H, Nofal A, Abdelmoety DA, Almatary A, Alsheef M, AlFayyad I. Epidemiology of Thalassemia in Gulf Cooperation Council Countries: A Systematic Review. Biomed Res Int 2020;2020:1509501. [PMID: 33178817 DOI: 10.1155/2020/1509501] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kontoghiorghes GJ. Advances on Chelation and Chelator Metal Complexes in Medicine. Int J Mol Sci 2020;21:E2499. [PMID: 32260293 DOI: 10.3390/ijms21072499] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
5 Kontoghiorghe CN, Kontoghiorghes GJ. New developments and controversies in iron metabolism and iron chelation therapy. World J Methodol 2016; 6(1): 1-19 [PMID: 27019793 DOI: 10.5662/wjm.v6.i1.1] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
6 Kontoghiorghes GJ, Kontoghiorghe CN. Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases. Cells 2020;9:E1456. [PMID: 32545424 DOI: 10.3390/cells9061456] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
7 Dusek P, Aaseth J. Chelating Therapy in Metal Storage Diseases. Chelation Therapy in the Treatment of Metal Intoxication. Elsevier; 2016. pp. 285-311. [DOI: 10.1016/b978-0-12-803072-1.00006-7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ. Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology. Molecules 2015;20:20841-72. [PMID: 26610453 DOI: 10.3390/molecules201119725] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
9 Kontoghiorghes GJ, Kontoghiorghe CN. Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology. Expert Opinion on Investigational Drugs 2019;28:593-603. [DOI: 10.1080/13543784.2019.1631284] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
10 Cheng R, Gadde R, Fan Y, Kulkarni N, Shevale N, Bao K, Choi HS, Betharia S, Kim J. Reversal of genetic brain iron accumulation by N,N'-bis(2-mercaptoethyl)isophthalamide, a lipophilic metal chelator, in mice. Arch Toxicol 2022. [PMID: 35445828 DOI: 10.1007/s00204-022-03287-1] [Reference Citation Analysis]
11 Taher AT, Porter JB, Kattamis A, Viprakasit V, Cappellini MD. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Des Devel Ther 2016;10:4073-8. [PMID: 28008230 DOI: 10.2147/DDDT.S117080] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther 2016;10:465-81. [PMID: 26893541 DOI: 10.2147/DDDT.S79458] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
13 Dusek P, Schneider SA, Aaseth J. Iron chelation in the treatment of neurodegenerative diseases. Journal of Trace Elements in Medicine and Biology 2016;38:81-92. [DOI: 10.1016/j.jtemb.2016.03.010] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 13.5] [Reference Citation Analysis]
14 Kontoghiorghes GJ, Kleanthous M, Kontoghiorghe CN. The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia. Mediterr J Hematol Infect Dis 2020;12:e2020011. [PMID: 31934321 DOI: 10.4084/MJHID.2020.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
15 Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ. Transfusion-Related Acute Lung Injury (TRALI) in two Thalassaemia Patients Caused by the Same Multiparous Blood Donor. Mediterr J Hematol Infect Dis 2017;9:e2017060. [PMID: 29181137 DOI: 10.4084/MJHID.2017.060] [Cited by in F6Publishing: 2] [Reference Citation Analysis]